LEADERSHIP

LEAD ASSET & PIPELINE

Lead asset

INHAL-101

INHAL-101 is a small molecule, PI3K/mTOR/BRD4 triple inhibitor administered as a stable dry powder for inhalation formulated using a proprietary mSAS® supercritical fluid technology.
INHAL-101 exhibits a dual competitive advantage with its unique triple-targeting Mechanism of Action (MoA), along with its industry-leading aerodynamic particle performance for lung delivery in patients with respiratory impairments.
INHAL-101 is a small molecule, PI3K/mTOR/BRD4 triple inhibitor administered as a stable dry powder for inhalation formulated using a proprietary mSAS® supercritical fluid technology.
INHAL-101 exhibits a dual competitive advantage with its unique triple-targeting Mechanism of Action (MoA), along with its industry-leading aerodynamic particle performance for lung delivery in patients with respiratory impairments.

THE MOLECULE
INHAL-101 has a unique MoA targeting three main pathways known to be key underlying causes of IPF, including the BRD4 target that is an important epigenetic modulator in pulmonary fibrosis. It showed a very selective binding profile, tested on high-throughput panels of targets including a 232 human kinase panel.

IPF pathogenesis and mOA of INHAL-101

One small molecule addressing the key pathways involved in IPF pathogenesis:

PI3K

PI3K exhibits overexpression in IPF, enabling signaling activity downstream of several key profibrotic growth factors.

mTOR

mTOR signaling axis inhibition blocks collagen synthesis in IPF. PI3K/mTOR pathway is strongly implicated in promoting fibroblast proliferation, survival and differentiation in response to various mediators.

BRD4

BRD4 is an epigenetic regulator for the expression of several profibrotic genes. BRD4 inhibition has been shown to reverse fibrosis in animal models.
INHAL-101 acts at the gene transcription level to block induction of profibrotic genes while targeting IPF pathogenesis at multiple levels by also blocking:
  • Growth factor signaling (including TGFβ)
  • Epithelial Mesenchymal Transition
  • Conversion of fibroblasts to activated myofibroblasts
  • Deposition of fibrotic extracellular matrix

Parental administration of INHAL-101 has demonstrated an excellent safety profile in all animal studies even up to 3 times the efficacy dosage. This systemic administration safety profile offers a comfortable safety window for administration through pulmonary inhalation.

In animal testing INHAL-101 was shown to be highly effective in preventing fibrosis development and disease progression with remarkably improved survival of 80% versus only 29% survival for the untreated group.

Thanks to its Mechanism of Acton, iINHAL-101 has the potentiality for stopping and even reversing fibrosis in certain cases.

The inhaled form, formulated with Industry leading mSAS ® technology, is delivered to deep lung up to 4X more than other technologies. Extensive histopathology studies of the entire respiratory tract, even at high doses, demonstrate no signs of irritation representing excellent tolerability and minimal risk of cough reflex. These studies confirm an important advantage in terms of treatment compliance in IPF patients. From pharmacokinetic studies only 1/3 of the inhaled dose passes out of the lung into the bloodstream where it is cleared very quickly thus minimizing any potential systemic side effects. Favorable high retention time in rat lung tissues as well as favorable kinetics were observed for inhaled INHAL-101.

mSAS® TECHNOLOGY
mSAS® is a scalable platform to generate stable high-performing particles in a 1-step process. The process achieves industry-leading particle delivery performance to reach the deep lung up to 4X more than other technologies showing excellent inhalation performance even at low inspiratory pressures characteristic of patients with respiratory impairment.

INHAL-101 Scanning Electron Microscopy (SEM) images before (left) and after (right) mSAS® processing: these images demonstrate the exceptional control of particle morphology and size for improved deep lung delivery.

pipeline

pipeline

Preclinical Proof-of-Concept obtained in several disease models including cancer and other fibrotic diseases along with pulmonary infections.

Preclinical Proof-of-Concept obtained in several disease models including cancer and other fibrotic diseases along with pulmonary infections.

Inhalis Therapeutics
Corso Elvezia, 4
CH-6900 Lugano
Switzerland

©2022 INHALIS

All rights reserved.

Policy  /  Credits